Methods for treating fibromyalgia syndrome

Patent metadata

Field	Value
Publication number	US-9688620-B2
Application number	US-201414495416-A
Country	US
Kind code	B2
Filing date	Sep 24, 2014
Priority date	Nov 6, 2009
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

First claim

The invention claimed is:

1. A method of treating fibromyalgia syndrome, comprising administering a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal suffering from fibromyalgia syndrome and in need of treatment:

wherein,
R is selected from the group consisting of hydrogen and lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy of 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R 1 and R 2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms; or
R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, and the nitrogen atoms are not directly connected with each other or with the oxygen atom.

2. The method of claim 1 , wherein the compound having structural Formula (1) is an enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the compound having structural Formula (1) predominates.

3. The method of claim 2 , wherein one enantiomer predominates to the extent of about 90% or greater.

4. The method of claim 3 , wherein one enantiomer predominates to the extent of about 98% or greater.

5. The method of claim 2 , wherein the enantiomer is (S) or (L) enantiomer as represented by Structural Formula (1a):

6. The method of claim 5 , wherein one enantiomer predominates to the extent of about 90% or greater.

7. The method of claim 6 , wherein one enantiomer predominates to the extent of about 98% or greater.

8. The method of claim 2 , wherein the enantiomer is (R) or (D) enantiomer, as represented by Structural Formula (1b):

9. The method of claim 8 , wherein one enantiomer predominates to the extent of about 90% or greater.

10. The method of claim 9 , wherein one enantiomer predominates to the extent of about 98% or greater.

11. The method of claim 1 , wherein R 1 and R 2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, phenyl, phenyl-methylenyl, or cycloalkyl of 3 to 7 carbon atoms.

Assignees

• Sk Biopharmaceuticals Co Ltd

Inventors

• Lee Sung James
• Melnick Susan Marie

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title